Drug intelligence / Profile preview

Flavolife 04

Development stage: Preclinical
Lead developer: Flavolife
Modality: Small Molecules

Overview

Flavolife 04 is a preclinical-stage small molecule pan-senolytic developed by Flavolife for the treatment of prostate cancer. Built upon a proprietary flavonoid scaffold platform, the drug is designed to selectively eliminate senescent cells. These cells, which cease to divide but remain metabolically active, contribute to the tumor microenvironment and disease progression through the senescence-associated secretory phenotype (SASP). By clearing senescent cells, Flavolife 04 aims to mitigate their pro-tumorigenic effects and improve therapeutic efficacy in prostate cancer.

Beyond the preview

Go deeper on Flavolife 04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flavolife 04.

Explore the full profile